Related Experiment Video
Updated: Jan 6, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Comparison of stem cell mobilization methods in multiple myeloma
Yutaka Shimazu1, Nobuhiro Tsukada2, Masaki Maruta3
1Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan..
Granulocyte colony-stimulating factor (G-CSF) based stem cell mobilization may improve survival outcomes for multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). This approach shows particular benefit for patients with suboptimal response before ASCT.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Novel therapies have improved multiple myeloma (MM) prognosis, but autologous stem cell transplantation (ASCT) remains crucial.
- Cyclophosphamide and G-CSF were standard for stem cell mobilization, but G-CSF±plerixafor (PLER) offers flexibility.
- Real-world data on mobilization practices and post-ASCT outcomes are limited.
Purpose of the Study:
- To evaluate the association between stem cell mobilization strategies and clinical outcomes in MM patients undergoing ASCT.
- To compare outcomes between cyclophosphamide-based and G-CSF±PLER-based mobilization.
Main Methods:
- Retrospective analysis of 3,319 MM patients undergoing ASCT between 2019-2022.
- Comparison of outcomes between patients mobilized with cyclophosphamide (n=743) and G-CSF±PLER (n=2,576).
- Primary endpoint: 2-year overall survival (OS); multivariate analysis and propensity score matching were used.
Main Results:
- Two-year OS rates were 89.7% for cyclophosphamide and 93.2% for G-CSF groups.
- G-CSF mobilization was an independent predictor of superior OS (P=0.005).
- Propensity score matching showed better OS in the G-CSF group (P=0.041), especially for patients without complete or very good partial response pre-ASCT.
Conclusions:
- G-CSF-based mobilization may confer prognostic advantages post-ASCT.
- This benefit is particularly noted in MM patients with suboptimal pre-ASCT response.
- G-CSF±PLER represents a potentially superior mobilization strategy for select MM patients.
